Wild type ALK

About

Gene context: ALK

Biomarker Type: Wild type

Present: True


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Cemiplimab HC
Sensitivity (+) Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed HC
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pembrolizumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pembrolizumab, Pemetrexed FDA
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab FDA
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab HC
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Tremelimumab HC
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab HC
Sensitivity (+) Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed FDA
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR Non-Small Cell Lung Cancer Cemiplimab FDA
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel FDA
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab HC
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed HC
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab HC
Sensitivity (+) PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab HC
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed FDA